Author:
Jean Guillaume,Souberbielle Jean-Claude,Zaoui Eric,Lorriaux Christie,Hurot Jean-Marc,Mayor Brice,Deleaval Patrik,Mehdi Manolie,Chazot Charles
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Wolf M. Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease. J Am Soc Nephrol. 2010;21(9):1427–35.
2. KDIGO C-M. Work Group KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int. 2009;76 Suppl 113:S1–130.
3. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26(4):622–31.
4. Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH, et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol. 2015;10(1):98–109.
5. Jean G, Bresson E, Lorriaux C, Mayor B, Hurot JM, Deleaval P, et al. Increased levels of serum parathyroid hormone and fibroblast growth factor-23 are the main factors associated with the progression of vascular calcification in long-hour hemodialysis patients. Nephron Clin Pract. 2012;120(3):c132–8.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献